Health & Biotech ResApp trial sends shares up 36pc as rollercoaster ride continues April 23, 2019 Shares in ResApp (ASX:RAP) have jumped 36 per cent this morning to six-month highs after it announced positive results from an… Dr Boreham’s Crucible: Are China and the US finally waking up to Compumedics? April 23, 2019 Perseverance is the byword at the Melbourne based Compumedics (ASX: CMP), which has become a global market leader in sleep… Biotech bosses vs investors: are you misunderstanding or are they bad at explaining? April 19, 2019 There has been a bit of confusion between biotech bosses and their shareholders this year. In November Mesoblast (ASX:MSB) boss… Creso doubles down on LatAm with Brazil cannabis import licence April 19, 2019 Special Report: Creso Pharma has won a Brazil import licence for its cannaQIX®50 medical cannabis. South America is the next… Suda Pharmaceuticals just got some bad news about its anti-malaria mouth spray April 19, 2019 Suda Pharmaceuticals (ASX: SUD) has had a setback in the development of its ArTiMist anti-malaria mouth spray. In short; it… Bacteria-killing biotech company Next Science broke onto the ASX with a 35 per cent gain April 18, 2019 Biotech company Next Science (ASX: NXS) has made an auspicious start to life as a listed company. It hit the… Health: Bubs gets national deal with Chemist Warehouse, extra China route, share spike April 18, 2019 Infant formula maker Bubs (ASX: BUB) has stitched up a deal with Chemist Warehouse, Australia's largest pharmacy retailer. The binding… MGC Pharma jumps on the China export train, shares rise 38pc April 18, 2019 Special Report: Biopharma company MGC Pharma will sell its CBD and hemp-based Nutraceuticals products in China thanks to a tie-up… Smiles takes ex-CEO, chair to court alleging illegal payments April 17, 2019 Smiles Inclusive (ASX:SIL) is taking its former CEO and chairman to court over allegations of illegal payments and transactions. The… Health: Paradigm in ‘no rush’ to partner with big pharma but analysts are alarmed April 17, 2019 The chief of knee pain biotech Paradigm Biopharmaceuticals (ASX:PAR) says his company is in no rush to take the tried-and-true exit strategy… Next» « Previous